Generation and application of 3D-organoid cell culture models using human induced
Presented At:
Gibco - 24 Hours of Stem Cells Virtual Event
Presented By:
Ryan Hicks - Associate Director - Stem & Primary Cell Group, AstraZeneca
Speaker Biography:
Ryan Hicks is the Associate Director of the Stem & Primary Cell Group at AstraZeneca. Ryan's group is responsible for the generation, engineering and differentiation of iPS cells, adult stem cells and use of primary cells for assay development, target validation, hit finding, hit-to-lead, lead optimization and phenotypic screening activities. Models are generated in 2D and 3D cultures and part of the model development work includes using precise genome modification techniques to introduce gene knock-outs, knock-in mutations or endogenous reporters into iPS cells. The groups work primarily focuses on AstraZeneca's cardiovascular, metabolic, renal and respiratory disease areas.
Webinar:
Generation and application of 3D-organoid cell culture models using human induced pluripotent stem cells (iPSCs) for drug discovery
Webinar Abstract:
Development of physiologically relevant cellular models, with strong translatability to human pathophysiology, is critical for identification and validation of novel therapeutic targets. Cell types derived from induced pluripotent stem cells (iPSCs) provide an important resource for modelling native biology in human cells and tissues for drug discovery. Understanding the phenotypic and functional relevance of these iPSC derived cells and tissues and how well they represent human biology is vital and as such we have developed tool iPSC-lines and techniques to optimize and monitor differentiation. Applying CRISPR/Cas9, Next Generation Sequencing (NGS), functional testing and advanced imaging techniques to iPSC model validation, we have established a platform that enables an accurate assessment of their benefits, maturity, gaps and challenges, as well as application in a drug discovery setting. Data presented will be from a key kidney model system we have developed to examplify our platforms. This will describe the validation and application of our kidney model, using SIX2 and NPHS1 markers non-invasively in real-time, to trace early nephron commitment and podocyte-maturation in the same cell. In adition, we will also describe how we use transcriptomic analysis by NGS, in addition to functional assays, to get the most from our iPS derived 3D cell models.
LabRoots on Social:
Facebook: https://www.facebook.com/LabRootsInc
Twitter: https://twitter.com/LabRoots
LinkedIn: https://www.linkedin.com/company/labroots
Instagram: https://www.instagram.com/labrootsinc
Pinterest: https://www.pinterest.com/labroots/
SnapChat: labroots_inc
Видео Generation and application of 3D-organoid cell culture models using human induced канала Labroots
Gibco - 24 Hours of Stem Cells Virtual Event
Presented By:
Ryan Hicks - Associate Director - Stem & Primary Cell Group, AstraZeneca
Speaker Biography:
Ryan Hicks is the Associate Director of the Stem & Primary Cell Group at AstraZeneca. Ryan's group is responsible for the generation, engineering and differentiation of iPS cells, adult stem cells and use of primary cells for assay development, target validation, hit finding, hit-to-lead, lead optimization and phenotypic screening activities. Models are generated in 2D and 3D cultures and part of the model development work includes using precise genome modification techniques to introduce gene knock-outs, knock-in mutations or endogenous reporters into iPS cells. The groups work primarily focuses on AstraZeneca's cardiovascular, metabolic, renal and respiratory disease areas.
Webinar:
Generation and application of 3D-organoid cell culture models using human induced pluripotent stem cells (iPSCs) for drug discovery
Webinar Abstract:
Development of physiologically relevant cellular models, with strong translatability to human pathophysiology, is critical for identification and validation of novel therapeutic targets. Cell types derived from induced pluripotent stem cells (iPSCs) provide an important resource for modelling native biology in human cells and tissues for drug discovery. Understanding the phenotypic and functional relevance of these iPSC derived cells and tissues and how well they represent human biology is vital and as such we have developed tool iPSC-lines and techniques to optimize and monitor differentiation. Applying CRISPR/Cas9, Next Generation Sequencing (NGS), functional testing and advanced imaging techniques to iPSC model validation, we have established a platform that enables an accurate assessment of their benefits, maturity, gaps and challenges, as well as application in a drug discovery setting. Data presented will be from a key kidney model system we have developed to examplify our platforms. This will describe the validation and application of our kidney model, using SIX2 and NPHS1 markers non-invasively in real-time, to trace early nephron commitment and podocyte-maturation in the same cell. In adition, we will also describe how we use transcriptomic analysis by NGS, in addition to functional assays, to get the most from our iPS derived 3D cell models.
LabRoots on Social:
Facebook: https://www.facebook.com/LabRootsInc
Twitter: https://twitter.com/LabRoots
LinkedIn: https://www.linkedin.com/company/labroots
Instagram: https://www.instagram.com/labrootsinc
Pinterest: https://www.pinterest.com/labroots/
SnapChat: labroots_inc
Видео Generation and application of 3D-organoid cell culture models using human induced канала Labroots
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Reference Materials: An Introduction to quality grades and an overview on the different types for...Anatomy of a diagnostic testCRISPR-Cas assisted genetics in intestinal organoidsPART 2: sigma Strong. How stronger harmonization builds better assays, simplifies quality control...Discover the WOLF G2 Cell Sorter, the latest in Microfluidic Gentle Cell Sorting for Immuno-OncologyHow to derive and expand primary tumor cell culturesDebunking Antibody Titration MythsCandida auris: PCR Screening for Infection PreventionSingle-Molecule Proteomics using Protein Identification by Short-epitope MappingExosomes: From pure isolation to standardized analysis by flow cytometrySimplicity that defies complexity the MACSima™ Platform for ultrahigh content imagingCoronavirus 2020The Fundamentals of Freeze Drying: Advice from the experts on how to get startedA CRISPR Cas12a Assisted in Vitro Diagnostic Tool for Identification and Quantification of Single CpTips & Tricks to Better Histology in Tissue Based Research Part 2 A review of key factors...Uterine B cell dynamics during pregnancy Immune regulation of the placenta 1Update on HBV testing and treatment: today and tomorrowMapping Tissues with In Situ Single-Cell TranscriptomicsKeeping up with the chemists - Cloud processing for pharma cryo-EMKeynote Presentation: Acidic Cannabinoids: Inactive Precursors or Powerful Therapeutics?Immunotoxicology assay toolbox: maximize standardization